ZA919694B - Labelled,modified oligonucleotides - Google Patents

Labelled,modified oligonucleotides

Info

Publication number
ZA919694B
ZA919694B ZA919694A ZA919694A ZA919694B ZA 919694 B ZA919694 B ZA 919694B ZA 919694 A ZA919694 A ZA 919694A ZA 919694 A ZA919694 A ZA 919694A ZA 919694 B ZA919694 B ZA 919694B
Authority
ZA
South Africa
Prior art keywords
labelled
modified oligonucleotides
useful
therapy
modified
Prior art date
Application number
ZA919694A
Other languages
English (en)
Inventor
Wilhelmus Henricus Ar Kuijpers
Henricus Arnoldus Ku Wilhelmus
Franciscus Michael Kaspersen
Michael Kaspersen Franciscus
Constant Adriaan Anton Boeckel
Adriaan Anton Van Boe Constant
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA919694B publication Critical patent/ZA919694B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pinball Game Machines (AREA)
ZA919694A 1990-12-10 1991-12-09 Labelled,modified oligonucleotides ZA919694B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9002714 1990-12-10

Publications (1)

Publication Number Publication Date
ZA919694B true ZA919694B (en) 1992-10-28

Family

ID=19858122

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA919694A ZA919694B (en) 1990-12-10 1991-12-09 Labelled,modified oligonucleotides

Country Status (15)

Country Link
EP (1) EP0490434B1 (de)
JP (1) JP3143506B2 (de)
KR (1) KR920012106A (de)
AT (1) ATE190621T1 (de)
AU (1) AU646118B2 (de)
CA (1) CA2057292A1 (de)
DE (1) DE69132044T2 (de)
ES (1) ES2144992T3 (de)
FI (1) FI915780A7 (de)
HU (1) HUT63191A (de)
IE (1) IE914220A1 (de)
NO (1) NO914839L (de)
NZ (1) NZ240926A (de)
PT (1) PT99752B (de)
ZA (1) ZA919694B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
EP0680335A1 (de) * 1992-11-30 1995-11-08 The Wellcome Foundation Limited Aufeinanderfolgendes zielen auf tumorstellen mit hilfe von an antikörper konjugierten oligonukleotiden und komplementäre oligonukleotidkonjugate von chelatierten radionukleiden
US5571680A (en) * 1994-01-21 1996-11-05 Beckman Instruments, Inc. Homogeneous immunoassays and enzyme based assays of analytes using capillary electrophoresis
IL114237A (en) * 1994-07-14 2000-08-31 Schering Ag Oligonucleotide conjugates and diagnostic processes utilizing the same
GB2291877B (en) * 1994-08-01 1998-09-23 Tom Robin Caine Boyde Interlinking at least two protein molecules via nucleic acid chains
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
US20010051348A1 (en) 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
WO2001054731A2 (en) * 2000-01-28 2001-08-02 National University Of Singapore Ligand conjugates and methods for preparing same
WO2001072203A2 (en) * 2000-03-24 2001-10-04 Temple University-Of The Commonwealth System Of Higher Education Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (de) * 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
WO1989005853A1 (en) * 1987-12-15 1989-06-29 Synthetic Genetics Nucleic acid chelate conjugate as therapeutic and diagnostic agents
AU3056889A (en) * 1988-01-21 1989-08-11 Yale University Selective inhibition of gene expression by photoactivatable oligonucleotides
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5109124A (en) * 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
CA2049028A1 (en) * 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH04500679A (ja) * 1989-04-18 1992-02-06 アメリカ合衆国 オリゴデオキシヌクレオチド化合物およびその製造方法

Also Published As

Publication number Publication date
CA2057292A1 (en) 1992-06-11
JP3143506B2 (ja) 2001-03-07
FI915780L (fi) 1992-06-11
NO914839D0 (no) 1991-12-09
JPH04290897A (ja) 1992-10-15
FI915780A7 (fi) 1992-06-11
EP0490434B1 (de) 2000-03-15
NO914839L (no) 1992-06-11
PT99752A (pt) 1992-11-30
DE69132044T2 (de) 2000-09-28
HU913867D0 (en) 1992-02-28
FI915780A0 (fi) 1991-12-09
ES2144992T3 (es) 2000-07-01
NZ240926A (en) 1993-11-25
PT99752B (pt) 1999-05-31
KR920012106A (ko) 1992-07-25
EP0490434A1 (de) 1992-06-17
HUT63191A (en) 1993-07-28
ATE190621T1 (de) 2000-04-15
AU8896091A (en) 1992-06-11
IE914220A1 (en) 1992-06-17
DE69132044D1 (de) 2000-04-20
AU646118B2 (en) 1994-02-10

Similar Documents

Publication Publication Date Title
PL318169A1 (en) Mammalian telomerase
HUT62010A (en) Process for producing oligonucleotide analogs comprising terminal 3 - 3, or 5 - 5- intermolecular bonds
PL336704A1 (en) Multivalent vaccine containing a mixed carrier
DE69214712D1 (de) Glykosylierte Arzneimittel-Vorstufen, Verfahren zu ihrer Herstellung und ihre Verwendungen
IL104696A0 (en) Dual carrier immunogenic construct and a vaccine containing the same
EP0554376A4 (en) Dna construct for providing rna therapy
EP0633943A4 (de) Gentherapy unter verwendung zielgerichteter viraler vektoren.
AU6953896A (en) Inverted chimeric and hybrid oligonucleotides
ZA919694B (en) Labelled,modified oligonucleotides
SE9704546D0 (sv) Novel compounds
AU5720498A (en) Chemical synthesis of nucleosides analogs and their incorporation into polynucleotides
FR2696744B1 (fr) Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
SE9803482D0 (sv) Ion exchange tumor targeting (IETT)
PL337177A1 (en) Novel class of agents constituting cationic transfectans of nucleic acids
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
BG101163A (bg) 8-флуоро-антрациклини, процеси за тяхното получаване и фармацевтични състави съдържащи ги
HUT72590A (en) Anomere fluoro-ribosyl-amines, intermediates thereof and process for preparing the said compos. and the pharmaceutical compns. contg. them
AU6997094A (en) Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them
AU682278B2 (en) Oligomer carrier molecules in which marker groups and haptens are selectively incorporated
ZA964925B (en) Pharmaceutical compositions for gene therapy.